KPF
JSPR icon

K2 Principal Fund’s Jasper Therapeutics JSPR Stock Holding History

K2 Principal Fund’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-825
Closed -$2.46M – 339
2021
Q2 		$2.46M Buy
825
+667
+422% +$1.99M 0.2% 143
2021
Q1 		$470K Buy
+158
New +$482K 0.04% 254

Other funds holding JSPR

Abingworth
Abingworth London, United Kingdom $304M AUM 95.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
LPARFS
Leverage Partners Absolute Return Fund SPC Cayman Islands Ky1-11111, Cayman Islands $54M AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return
Tower Research Capital (TRC)
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

K2 Principal Fund's JSPR Position: Q3 2021 in Review

K2 Principal Fund sold out of Jasper Therapeutics (JSPR) in Q3 2021, closing a stake of 825 shares — an estimated $2.46M sold.

K2 Principal Fund first reported a position in JSPR in Q1 2021 and held it in 2 quarters. The position peaked at $2.46M in Q2 2021. 10 funds tracked by Wall St. Rank hold JSPR as of Q3 2021.

  • K2 Principal Fund reported no remaining Jasper Therapeutics position as of Q3 2021 after selling out during the quarter.
  • K2 Principal Fund sold 825 Jasper Therapeutics shares in Q3 2021, an estimated $2.46M.
  • K2 Principal Fund first reported a position in Jasper Therapeutics in Q1 2021 and held it in 2 quarters.
  • K2 Principal Fund's Jasper Therapeutics position peaked at $2.46M in Q2 2021.
  • 10 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q3 2021.

Based on K2 Principal Fund's 13F filing for Q3 2021, filed 12 Nov 2021.